Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23265894)

1.

Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.

Staben ST, Blaquiere N, Tsui V, Kolesnikov A, Do S, Bradley EK, Dotson J, Goldsmith R, Heffron TP, Lesnick J, Lewis C, Murray J, Nonomiya J, Olivero AG, Pang J, Rouge L, Salphati L, Wei B, Wiesmann C, Wu P.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):897-901. doi: 10.1016/j.bmcl.2012.10.121. Epub 2012 Nov 5.

PMID:
23265894
2.

Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.

Staben ST, Siu M, Goldsmith R, Olivero AG, Do S, Burdick DJ, Heffron TP, Dotson J, Sutherlin DP, Zhu BY, Tsui V, Le H, Lee L, Lesnick J, Lewis C, Murray JM, Nonomiya J, Pang J, Prior WW, Salphati L, Rouge L, Sampath D, Sideris S, Wiesmann C, Wu P.

Bioorg Med Chem Lett. 2011 Jul 1;21(13):4054-8. doi: 10.1016/j.bmcl.2011.04.124. Epub 2011 May 13.

PMID:
21636270
3.

Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.

Staben ST, Ndubaku C, Blaquiere N, Belvin M, Bull RJ, Dudley D, Edgar K, Gray D, Heald R, Heffron TP, Jones GE, Jones M, Kolesnikov A, Lee L, Lesnick J, Lewis C, Murray J, McLean NJ, Nonomiya J, Olivero AG, Ord R, Pang J, Price S, Prior WW, Rouge L, Salphati L, Sampath D, Wallin J, Wang L, Wei B, Weismann C, Wu P.

Bioorg Med Chem Lett. 2013 May 1;23(9):2606-13. doi: 10.1016/j.bmcl.2013.02.102. Epub 2013 Mar 7.

PMID:
23540645
4.

Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.

Yang H, Hendricks RT, Arora N, Nitzan D, Yee C, Lucas MC, Yang Y, Fung A, Rajyaguru S, Harris SF, Leveque VJ, Hang JQ, Pogam SL, Reuter D, Tavares GA.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4614-9. doi: 10.1016/j.bmcl.2010.06.008. Epub 2010 Jun 8.

PMID:
20584604
5.

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.

Pecchi S, Ni ZJ, Han W, Smith A, Lan J, Burger M, Merritt H, Wiesmann M, Chan J, Kaufman S, Knapp MS, Janssen J, Huh K, Voliva CF.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4652-6. doi: 10.1016/j.bmcl.2013.06.010. Epub 2013 Jun 12.

PMID:
23820386
6.

Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.

Ramurthy S, Costales A, Jansen JM, Levine B, Renhowe PA, Shafer CM, Subramanian S.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1678-81. doi: 10.1016/j.bmcl.2011.12.112. Epub 2011 Dec 30.

PMID:
22264479
7.

Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.

Ramurthy S, Aikawa M, Amiri P, Costales A, Hashash A, Jansen JM, Lin S, Ma S, Renhowe PA, Shafer CM, Subramanian S, Sung L, Verhagen J.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3286-9. doi: 10.1016/j.bmcl.2011.04.023. Epub 2011 Apr 14.

PMID:
21543226
8.

Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.

Moretto AF, Kirincich SJ, Xu WX, Smith MJ, Wan ZK, Wilson DP, Follows BC, Binnun E, Joseph-McCarthy D, Foreman K, Erbe DV, Zhang YL, Tam SK, Tam SY, Lee J.

Bioorg Med Chem. 2006 Apr 1;14(7):2162-77. Epub 2005 Nov 21.

PMID:
16303309
9.

Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.

Ashton KS, St Jean DJ Jr, Poon SF, Lee MR, Allen JG, Zhang S, Lofgren JA, Zhang X, Fotsch C, Hungate R.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5191-6. doi: 10.1016/j.bmcl.2011.07.056. Epub 2011 Jul 23.

PMID:
21824779
10.

Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.

Scheiper B, Matter H, Steinhagen H, Böcskei Z, Fleury V, McCort G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5480-6. doi: 10.1016/j.bmcl.2011.06.114. Epub 2011 Jul 6.

PMID:
21840218
11.

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.

Jones P, Bottomley MJ, Carfí A, Cecchetti O, Ferrigno F, Lo Surdo P, Ontoria JM, Rowley M, Scarpelli R, Schultz-Fademrecht C, Steinkühler C.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3456-61. doi: 10.1016/j.bmcl.2008.02.026. Epub 2008 Feb 14.

PMID:
18440229
12.

Analogs of the dihydroceramide desaturase inhibitor GT11 modified at the amide function: synthesis and biological activities.

Bedia C, Triola G, Casas J, Llebaria A, Fabriàs G.

Org Biomol Chem. 2005 Oct 21;3(20):3707-12. Epub 2005 Sep 8.

PMID:
16211106
13.

MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.

Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM.

Bioorg Med Chem Lett. 2011 May 15;21(10):2820-2. doi: 10.1016/j.bmcl.2011.03.099. Epub 2011 Apr 1.

PMID:
21507637
14.

Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system.

Wolin R, Connolly M, Kelly J, Weinstein J, Rosenblum S, Afonso A, James L, Kirschmeier P, Bishop WR.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2521-6.

PMID:
9873573
15.

Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.

Wan ZK, Lee J, Xu W, Erbe DV, Joseph-McCarthy D, Follows BC, Zhang YL.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4941-5. Epub 2006 Jun 27.

PMID:
16806920
16.

1,5-Substituted nipecotic amides: selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability.

DeNinno MP, Wright SW, Visser MS, Etienne JB, Moore DE, Olson TV, Rocke BN, Andrews MP, Zarbo C, Millham ML, Boscoe BP, Boyer DD, Doran SD, Houseknecht KL.

Bioorg Med Chem Lett. 2011 May 15;21(10):3095-8. doi: 10.1016/j.bmcl.2011.03.022. Epub 2011 Mar 11.

PMID:
21459572
17.

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.

Baxter A, Brough S, Cooper A, Floettmann E, Foster S, Harding C, Kettle J, McInally T, Martin C, Mobbs M, Needham M, Newham P, Paine S, St-Gallay S, Salter S, Unitt J, Xue Y.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2817-22.

PMID:
15125939
18.

Identification of pyrimidine derivatives as hSMG-1 inhibitors.

Gopalsamy A, Bennett EM, Shi M, Zhang WG, Bard J, Yu K.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41. doi: 10.1016/j.bmcl.2012.08.107. Epub 2012 Sep 7.

PMID:
23021994
19.

Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).

Moffett K, Konteatis Z, Nguyen D, Shetty R, Ludington J, Fujimoto T, Lee KJ, Chai X, Namboodiri H, Karpusas M, Dorsey B, Guarnieri F, Bukhtiyarova M, Springman E, Michelotti E.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7155-65. doi: 10.1016/j.bmcl.2011.09.078. Epub 2011 Sep 28.

PMID:
22014550
20.

2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.

Dai C, Li D, Popovici-Muller J, Zhao L, Girijavallabhan VM, Rosner KE, Lavey BJ, Rizvi R, Shankar BB, Wong MK, Guo Z, Orth P, Strickland CO, Sun J, Niu X, Chen S, Kozlowski JA, Lundell DJ, Piwinski JJ, Shih NY, Siddiqui MA.

Bioorg Med Chem Lett. 2011 May 15;21(10):3172-6. doi: 10.1016/j.bmcl.2011.01.002. Epub 2011 Jan 6.

PMID:
21458257
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk